Statements
Response to SMC Decision to accept Eylea for wet AMD
Statement from The Royal College of Ophthalmologists The Royal College of Ophthalmologists welcomes the SMC decision to recommend Aflibercept (Eylea®) as a treatment for neovascular AMD. Aflibercept is a soluble vascular endothelial growth factor (VEGF) receptor fusion protein which binds to all forms of VEGF and inhibits its actions. This drug has been shown in
Eye health professionals welcome the first ever Public Health Indicator for eye health
Eye health professionals from across the sector will welcome the first ever Public Health Indicator for eye health when it comes into force on April 1st, 2013. As part of the new Public Health Outcomes Framework, the Indicator will track changes in the numbers of people who are certified as blind or partially sighted and
Review of ranibizumab in patients with diabetic macular oedema
Statement on the rapid review of the technology appraisal of the use of intravitreal ranibizumab in patients with diabetic macular oedema (DMO) Review of Ranibizumab for DMO
NICE rapid review of previous technology appraisal – intravitreal ranibizumab with DMO
College Statement The National Institute of Clinical Excellence (NICE) has completed a rapid review of the previous technology appraisal of the use of intravitreal ranibizumab in patients with diabetic macular oedema. The new guidance document on ranibizumab for diabetic macular oedema, (TA274), published on 27 February 2013, recommends that patients with DMO can be commenced
Eye health professionals raise alarm over reports of growing number of patients denied cataract surgery
Royal College of Ophthalmologists, College of Optometrists, OpticalConfederation and Local Optical Committee Support Unit issue joint statement London, 13 August 2012 The Royal College of Ophthalmologists has expressed its concern over reports that patients in more than half of PCTs in England are being denied cataract surgery unless their ability to read the optometrists’ test